ABN Newswire http://www.abnnewswire.net Wed, 30 May 2012 01:10:56 newsroom@abnnewswire.net newsroom@abnnewswire.net 60 <![CDATA[ Asian Activities Report for January 9, 2012: Little Sheep Group (HKG:0968) Shareholders Approved Yum! Brands (NYSE:YUM) Takeover Offer ]]> en71231 Y http://www.abnnewswire.net/press/en/71231/ Mon, 9 Jan 2012 13:00:25 GMT Little Sheep Group Limited (HKG:0968) says that its shareholders have approved the proposed acquisition of Little Sheep Group by Yum! Brands, Inc. (NYSE:YUM), the US-based fast food company which owns KFC and Pizza Hut. Regulatory approvals from the Chinese authorities have also been granted. The acquisition of Little Sheep, in which Yum already owns nearly 30%, will further boost Yum's presence in China.

Sinopec Kantons Holdings Limited (HKG:0934) has signed agreements to acquire 50% interest in Fujairah Oil Terminal ("FOT") in the United Arab Emirates from Concord HK. FOT will principally engage in operating oil storage facilities in the United Arab Emirates and will develop an oil storage project with a capacity of 1,125,000 cubic metres in the United Arab Emirates.

Hitachi, Ltd (NYSE:HIT) (TYO:6510) says that it expects to close the transaction of transferring its hard disk drive business to Western Digital Corporation (NYSE:WDC) by March 2012, subject to the completion of obtaining approvals from European Commission and other regulatory authorities. On March 7, 2011, Western Digital Corporation agreed to buy Hitachi Global Storage Technologies, the hard drive and storage business owned by Hitachi for approximately US$4.3 billion.

Japanese software developer Celartem Technology Inc. (JASDAQ:4330) has signed a contract to participate in a smart micro grid project at the Beijing New Energy Industry Base. The total investment for the project is estimated at 124.88 million RMB.

Takeda Pharmaceutical Company Limited (TYO:4502) says that it will work with Osaka University to develop a platform for practical application and commercialization of nano-particle vaccines. Takeda launched the Vaccine Business Division on January 1, 2012, aiming to expand its vaccine business outside of Japan. The collaboration with Osaka University as part of Takeda's vaccine strategy, will contribute further to the development of innovative technology in the vaccine industry

Qiubei Fu
Asia Business News
Tel: +61-2-9247-4344
http://www.abnnewswire.net

]]> newsroom@abnnewswire.net <![CDATA[ Wincor Nixdorf's (FRA:WIN) 100,000 Self-Service Devices On Five Continents Monitored Using ProView ]]> en59637 Y http://www.abnnewswire.net/press/en/59637/ Wed, 26 Nov 2008 14:51:06 GMT
Some of the financial institutions using ProView are Raiffeisen Bank Group in Austria, Halkbank in Turkey, CIMB Bank in Malaysia and Susquehanna Bancshares in the U.S. The software has even taken on the lead in Eastern Europe - two of ProView's many users in this region are leading retail banks in the Ukraine, Privatbank and Nadra Bank.

ProView has been adapted to address the particular requirements of self-service equipment of all kinds. All transaction data is analyzed by the ProView agent on the terminal level and is transferred to the ProView server for processing and output. In particular, ProView ensures high system availability: precise and detailed information on the operating state of each terminal device enables fast, targeted resolution of any problems. Remote service means repairs can be carried out via electronic access from a central location, ensuring that device downtimes and site visits by technicians can be minimized. As a result, this solution leads to highly relevant cost savings and increases the overall profitability of the institution's self-service network.

In addition, ProView makes a highly effective contribution to protecting automated teller machines from manipulation. Wincor Nixdorf's anti-skimming module monitors the entire area around the card input slot. If it senses that a foreign device has been mounted there, it sends a message - known as an "event" - to ProView. This message brings about the immediate initiation of a variety of defensive measures. These and other actions offer customers comprehensive security, and ensure that self-service devices can be put back into service rapidly and are consequently highly available.

In order to simplify service management processes, ProView has been expanded to incorporate a new function for incident management - Incident Manager. When an error occurs, a ticket is opened that documents every individual process step, stores information and displays the current status of the repair work.

Third-party systems can be integrated easily into ProView. ProView can be deployed not only on decentralized systems at the branch level, but also centrally at the head office or at a shared data center or external systems management center. To control the network, ProView offers extensive reports and the option of connection to business intelligence products that automatically identify the key indicators on device performance and availability.

Andreas Bruck
Head of Corporate Communications
Phone: +49 5251 693 5200
E-Mail: andreas.bruck@wincor-nixdorf.com

]]> newsroom@abnnewswire.net <![CDATA[ MorphoSys Enters Therapeutic Research Collaboration on Novel Target Molecule with Genesis Research ]]> en42621 Y http://www.abnnewswire.net/press/en/42621/ Mon, 8 Oct 2007 20:45:15 GMT
Under the terms of the agreement, Genesis will continue to use HuCAL-based antibodies originally generated by the MorphoSys business unit AbD Serotec against the human fibroblast growth factor receptor FGFR5 for target validation and pre-clinical studies as part of its proprietary Zyrogen program. In this program, Genesis is investigating the development of therapeutic antibodies specific for the target molecule FGFR5, which is implicated in various autoimmune and bone-related diseases. Based on the scientific data generated by Genesis during the collaboration, the parties will discuss further development of the therapeutic program.

Financial details of the agreement were not disclosed.

The underlying target molecule FGFR5 (fibroblast growth factor receptor 5), a cell surface protein expressed by stromal cells of the hemopoietic system, was originally identified by Genesis from its proprietary EST databases. Genesis has carried out extensive studies to characterize the molecule's interactions with different cell types and tissues, suggesting that it is a therapeutic target for diseases such as osteoporosis, systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. With the signing of this agreement, Genesis will continue to extend its strong patent position around this molecule using the HuCAL antibodies and will further validate its approach through in vitro and in vivo studies as a necessary prelude to a clinical development program.

"The collaboration with Genesis provides us with access to an innovative and scientifically attractive target molecule which may lead to lucrative future commercial opportunities for MorphoSys," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "At the same time, it is a further example of the synergies arising between our two business segments, as satisfied AbD Serotec customers decide to partner with MorphoSys for the development of their therapeutic or diagnostic projects."

"AbD Serotec have provided excellent technical advice and service", said Stephen Hall, Chief Executive Officer of Genesis Research. "We value the opportunity to work with MorphoSys Group to develop our therapeutic monoclonal antibodies which have great potential to help treat several diseases where there are limited treatments."

HuCAL(tm) and HuCAL GOLD(tm) are registered trademarks of MorphoSys AG

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

MorphoSys AG 

Dave Lemus
Chief Financial Officer
Tel: +49 (0) 89 / 899 27-439
Fax: +49 (0) 89 / 899 27-5439
investors@morphosys.com

Mario Brkulj
Manager Public Relations
Tel: +49 (0) 89 / 899 27-454
Fax: +49 (0) 89 / 899 27-5454
brkulj@morphosys.com

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications
Tel: +49 (0) 89 / 899 27-122
Fax: +49 (0) 89 / 899 27-5122
gutjahr-loeser@morphosys.com

Genesis Research & Development 

Chief Executive
Tel: +64 21 715 725
s.hall@genesis.co.nz

Dr. Greg Murison
Chief Scientific Officer
Tel: +64 21 227 7484
Stephen Hall

]]> newsroom@abnnewswire.net <![CDATA[ IBA shares in Trading Halt During Roadshow to Raise Capital for Possible iSOFT Acquisition ]]> en36377 Y http://www.abnnewswire.net/press/en/36377/ Mon, 7 May 2007 10:19:31 GMT
The trading halt is to enable IBA to hold meetings with certain institutional investors with a view to raising new equity capital to facilitate a possible recommended all-share offer for iSOFT Group plc, listed in the UK. The iSOFT management team is participating in these meetings.

Under the proposed merger terms iSOFT shareholders would receive 1.1 new IBA shares for each iSOFT share. This would value iSOFT at A$1.38 (56.9 pence) per share based on the last trading price of IBA shares on the ASX and a GBP:A$ exchange rate of 0.4121.

IBA is seeking to raise equity capital of approximately A$200 million through an institutional placement and a rights issue to existing shareholders. Both the placement and the rights issue would be fully underwritten by ABN AMRO Rothschild.

In addition to the above equity issuance, the transaction would be supported with new debt facilities totalling A$315 million to be arranged and underwritten by ABN AMRO Bank N.V. subject to completion of a number of conditions precedent including the completion of the equity placement/issuance.

There can be no certainty that an offer by IBA to acquire iSOFT will be made. If the merger proceeded, it would produce the world's fourth largest healthcare information technology company, and full run rate annual cost synergies from combining the two companies would be expected to total approximately A$27 million in the year to 30 June 2009.

IBA will continue to inform investors of developments.

Notice of Dealing Disclosure Requirements Under The UK City Code on Takeovers and Mergers

Under the provisions of Rule 8.3 of the Takeover Code (the "Code"), if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of IBA Health Limited or of iSOFT Group plc, all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3.30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer period" otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an "interest" in "relevant securities" of IBA Health Limited or iSOFT Group plc, they will be deemed to be a single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant securities" of IBA Health Limited, or of iSOFT Group plc by IBA Health Limited or iSOFT Group plc, or by any of their respective "associates", must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose "relevant securities","dealgs" should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel's website at www.thetakeoverpanel.org.uk.

"Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Code, which can also be found on the Panel's website.

Gary Cohen
Executive Chairman
IBA Health Limited
Phone: +61 2 8251 6700

Email: gary.cohen@ibahealth.com
	

Media
Greg King
Communications and Business Development Director
IBA Health Limited
Phone: +61 413 621 111

Email: greg.king@ibahealth.com

]]> newsroom@abnnewswire.net <![CDATA[ CyGenics' Subsidiary Signs Distribution Agreement with CombiMatrix ]]> en30903 Y http://www.abnnewswire.net/press/en/30903/ Wed, 30 Nov 2005 09:13:49 GMT
Under the terms of the agreement, Cell Sciences will market and sell CustomArrays(tm), CatalogArrays(tm) and CustomArray Synthesizers, which are semiconductor-based tools for use in identifying and determining the roles of genes, and the recently introduced Influenza Research Microarray, to the Southeast Asian market.

"We are very pleased to have expanded our distribution network into Southeast Asia," said Michael Tognotti, Vice President of Sales and Marketing for CombiMatrix. "I am confident that by joining forces with Cell Sciences, we can accelerate sales growth and enhance our collective market share." "Cell Sciences has identified CombiMatrix's platform technology to rapidly produce customizable arrays for applications in the areas of proteomics, genomics and nanotechnology," said Mr Steven Fang, Group CEO, CyGenics. "This has a huge market potential in the Asia Pacific region and we look forward to a long and fruitful relationship."

About Cell Sciences
Cell Sciences is a subsidiary of CyGenics which is listed in the Australian Stock Exchange (ASX). It has an established network covering Singapore, Malaysia, Thailand, Indonesia, Philippines, Hong Kong, China, Australia and USA. Cell Sciences is a supplier of diagnostics for life science research and manufactures proprietary products.

Cell Sciences drives the sales, marketing and distribution for biomedical products. In Jan 2004, the company launched a patented 3-D growth scaffold and the market's first disposable cell culture spinner systems. Cell Sciences markets products targeting an extensive customer base comprising laboratories (research, clinical and bioprocessing), industry (biopharmaceuticals), specialists and hospitals. The company focuses on product lines core to the strategic business of the CyGenics Group in areas of stem cell biotechnology and regenerative medicines, as well as products that add to a more comprehensive offering to the customers we serve.

www.cygenics.com/cellsciences

]]> newsroom@abnnewswire.net